NeuroBo Pharmaceuticals (NRBO) announced the completion of the last patient last visit in its two-part, Phase 2a clinical trial evaluating the efficacy and safety of DA-1241, a novel G-Protein-Coupled Receptor 119 agonist for the treatment of metabolic dysfunction-associated steatohepatitis. Topline data readout from part 1 and part 2 is expected in December.
Education
About Us
Working with TipRanks
Follow Us
1